Valeant Pharma's (VRX) Relistor Said to Draw Interest from Potential Buyers
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
(Updated - August 5, 2016 12:17 PM EDT)
Valeant Pharma's (NYSE: VRX) Relistor said to have drawn interest from potential buyers, according to Bloomberg.
UPDATE - Other drugmakers may be interested in the asset, sources said.
Relistor could get around $400 - $500 million in a potential sale.
News comes as Valeant works to get a $30 billion debtload under control, while also looking to ease public concerns over drug pricing and the company's business practices, which have taken center stage this year.
Progenics Pharma (Nasdaq: PGNX) is Valeant's partner on Relistor. The drug is indicated to treat constipation brought on by taking opioids for chronic, non-cancer pain.
Shares of Valeant are down 0.7 percent.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jim Chanos Negative Again on Valeant Pharma (VRX) in CNBC Interview
- UPDATE: Barrick Gold (ABX) Gains; Chinese Miners Said in Talks for Stake in Veladero Mine - Reuters
- Ziopharm Oncology (ZIOP) Said to Cancel Mizuho Conference - Chatter
Create E-mail Alert Related CategoriesMergers and Acquisitions, Rumors, Short Sales, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!